A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Local Institution - 0012, Brussels

Local Institution - 0016, Sydney

Local Institution - 0017, Waratah

Local Institution - 0032, Leuven

Local Institution - 0027, Malvern

Local Institution - 0015, Clayton

Local Institution - 0045, Liège

Local Institution - 0031, Chermside

Local Institution - 0013, Namur

Local Institution - 0053, Seoul

Local Institution - 0058, Nedlands

Local Institution - 0020, Girona

Local Institution - 0011, Milan

Local Institution - 0009, Milan

Local Institution - 0002, Brescia

Local Institution - 0005, Madrid

Local Institution - 0038, Madrid

Local Institution - 0001, Madrid

Local Institution - 0022, Madrid

Local Institution - 0054, Haifa

Local Institution - 0003, Bologna

Local Institution - 0061, Columbus

Local Institution - 0007, Valencia

Local Institution - 0006, Valencia

Local Institution - 0048, Tel Aviv

Local Institution - 0043, Kansas City

Local Institution - 0082, Salt Lake City

Local Institution - 0080, Jerusalem

Local Institution - 0025, San Francisco

Local Institution - 0065, Sacramento

Local Institution - 0042, Spokane

Local Institution - 0029, Temuco

Local Institution - 0055, Ramat Gan

Local Institution - 0036, Santiago

Local Institution - 0030, Santiago

Local Institution - 0046, Jerusaelm

Local Institution - 0078, Whittier

Local Institution - 0081, South Bend

Local Institution - 0023, Canton

Local Institution - 0044, Nashville

Local Institution - 0010, Roma

Local Institution - 0018, Akashi, Hyogo

Local Institution - 0019, Chūōku

Local Institution - 0014, Hidaka-shi

Local Institution - 0004, Kurume-Shi

Local Institution - 0037, Tokyo

Local Institution - 0056, Seoul

Local Institution - 0049, Seoul

Local Institution - 0039, Barcelona

Local Institution - 0021, Barcelona